Wanbangde Pharmaceutical Holding Group Co., Ltd. (002082.SZ)
CNY 7.0
(-2.51%)
CNY 7.0
(-2.51%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.53 Billion CNY | 10.09% |
| 2022 | 1.39 Billion CNY | -14.15% |
| 2021 | 1.62 Billion CNY | -41.99% |
| 2020 | 2.8 Billion CNY | 48.47% |
| 2019 | 1.88 Billion CNY | 68.37% |
| 2018 | 1.12 Billion CNY | 125.9% |
| 2017 | 496.58 Million CNY | 89.65% |
| 2016 | 261.84 Million CNY | -3.12% |
| 2015 | 270.28 Million CNY | 6.12% |
| 2014 | 254.69 Million CNY | -29.46% |
| 2013 | 361.07 Million CNY | -23.03% |
| 2012 | 469.09 Million CNY | 19.6% |
| 2011 | 392.22 Million CNY | 3.09% |
| 2010 | 380.45 Million CNY | 23.77% |
| 2009 | 307.38 Million CNY | -0.67% |
| 2008 | 309.46 Million CNY | -39.62% |
| 2007 | 512.51 Million CNY | 3.78% |
| 2006 | 493.84 Million CNY | -2.95% |
| 2005 | 508.84 Million CNY | 81.42% |
| 2004 | 280.48 Million CNY | 72.03% |
| 2003 | 163.04 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.61 Billion CNY | 5.28% |
| 2024 Q2 | 1.52 Billion CNY | -5.47% |
| 2024 Q3 | 1.5 Billion CNY | -1.64% |
| 2023 Q2 | 1.6 Billion CNY | 0.13% |
| 2023 Q4 | 1.53 Billion CNY | -7.22% |
| 2023 Q3 | 1.65 Billion CNY | 3.26% |
| 2023 FY | 1.53 Billion CNY | 10.09% |
| 2023 Q1 | 1.6 Billion CNY | 14.76% |
| 2022 Q1 | 1.39 Billion CNY | -14.5% |
| 2022 FY | 1.39 Billion CNY | -14.15% |
| 2022 Q4 | 1.39 Billion CNY | 8.22% |
| 2022 Q3 | 1.29 Billion CNY | 4.54% |
| 2022 Q2 | 1.23 Billion CNY | -11.25% |
| 2021 Q1 | 1.4 Billion CNY | -49.95% |
| 2021 FY | 1.62 Billion CNY | -41.99% |
| 2021 Q3 | 1.34 Billion CNY | 2.42% |
| 2021 Q2 | 1.31 Billion CNY | -6.51% |
| 2021 Q4 | 1.62 Billion CNY | 21.05% |
| 2020 FY | 2.8 Billion CNY | 48.47% |
| 2020 Q2 | 2.26 Billion CNY | -4.58% |
| 2020 Q3 | 2.41 Billion CNY | 6.89% |
| 2020 Q4 | 2.8 Billion CNY | 15.95% |
| 2020 Q1 | 2.37 Billion CNY | 25.55% |
| 2019 Q3 | 1.8 Billion CNY | 30.1% |
| 2019 Q4 | 1.88 Billion CNY | 4.39% |
| 2019 FY | 1.88 Billion CNY | 68.37% |
| 2019 Q1 | 951.73 Million CNY | -15.16% |
| 2019 Q2 | 1.39 Billion CNY | 46.12% |
| 2018 Q2 | 835 Million CNY | 92.8% |
| 2018 FY | 1.12 Billion CNY | 125.9% |
| 2018 Q4 | 1.12 Billion CNY | 22.82% |
| 2018 Q3 | 913.33 Million CNY | 9.38% |
| 2018 Q1 | 433.09 Million CNY | -12.79% |
| 2017 Q1 | 268.74 Million CNY | 2.63% |
| 2017 Q2 | 286.03 Million CNY | 6.43% |
| 2017 FY | 496.58 Million CNY | 89.65% |
| 2017 Q3 | 251.9 Million CNY | -11.93% |
| 2017 Q4 | 496.58 Million CNY | 97.13% |
| 2016 Q3 | 225.87 Million CNY | -7.4% |
| 2016 FY | 261.84 Million CNY | -3.12% |
| 2016 Q4 | 261.84 Million CNY | 15.93% |
| 2016 Q2 | 243.93 Million CNY | -0.76% |
| 2016 Q1 | 245.8 Million CNY | -9.06% |
| 2015 Q2 | 249.72 Million CNY | 3.92% |
| 2015 Q1 | 240.31 Million CNY | -5.64% |
| 2015 FY | 270.28 Million CNY | 6.12% |
| 2015 Q4 | 270.28 Million CNY | -0.61% |
| 2015 Q3 | 271.94 Million CNY | 8.9% |
| 2014 Q1 | 362.39 Million CNY | 0.37% |
| 2014 FY | 254.69 Million CNY | -29.46% |
| 2014 Q2 | 318.12 Million CNY | -12.22% |
| 2014 Q4 | 254.69 Million CNY | -24.69% |
| 2014 Q3 | 338.17 Million CNY | 6.3% |
| 2013 Q3 | 417.04 Million CNY | -11.44% |
| 2013 Q2 | 470.94 Million CNY | -20.0% |
| 2013 Q1 | 588.67 Million CNY | 25.49% |
| 2013 FY | 361.07 Million CNY | -23.03% |
| 2013 Q4 | 361.07 Million CNY | -13.42% |
| 2012 Q4 | 469.09 Million CNY | -17.73% |
| 2012 Q2 | 533.84 Million CNY | 21.18% |
| 2012 Q3 | 570.17 Million CNY | 6.8% |
| 2012 Q1 | 440.55 Million CNY | 12.32% |
| 2012 FY | 469.09 Million CNY | 19.6% |
| 2011 Q3 | 546.44 Million CNY | 16.99% |
| 2011 Q4 | 392.22 Million CNY | -28.22% |
| 2011 FY | 392.22 Million CNY | 3.09% |
| 2011 Q2 | 467.06 Million CNY | 19.4% |
| 2011 Q1 | 391.16 Million CNY | 2.82% |
| 2010 Q2 | 378.3 Million CNY | -21.29% |
| 2010 FY | 380.45 Million CNY | 23.77% |
| 2010 Q1 | 480.6 Million CNY | 56.35% |
| 2010 Q4 | 380.45 Million CNY | -6.27% |
| 2010 Q3 | 405.89 Million CNY | 7.29% |
| 2009 Q1 | 363.07 Million CNY | 17.33% |
| 2009 Q3 | 455.99 Million CNY | 45.6% |
| 2009 Q2 | 313.18 Million CNY | -13.74% |
| 2009 FY | 307.38 Million CNY | -0.67% |
| 2009 Q4 | 307.38 Million CNY | -32.59% |
| 2008 Q2 | 532.03 Million CNY | 7.5% |
| 2008 Q4 | 309.46 Million CNY | -43.72% |
| 2008 Q3 | 549.86 Million CNY | 3.35% |
| 2008 FY | 309.46 Million CNY | -39.62% |
| 2008 Q1 | 494.89 Million CNY | -3.44% |
| 2007 Q4 | 512.51 Million CNY | -9.5% |
| 2007 Q2 | 436.5 Million CNY | -4.5% |
| 2007 Q1 | 457.06 Million CNY | -7.45% |
| 2007 Q3 | 566.29 Million CNY | 29.74% |
| 2007 FY | 512.51 Million CNY | 3.78% |
| 2006 Q2 | 673.29 Million CNY | 0.0% |
| 2006 Q3 | 732.32 Million CNY | 8.77% |
| 2006 Q4 | 493.84 Million CNY | -32.56% |
| 2006 FY | 493.84 Million CNY | -2.95% |
| 2005 FY | 508.84 Million CNY | 81.42% |
| 2005 Q4 | 508.84 Million CNY | 0.0% |
| 2004 FY | 280.48 Million CNY | 72.03% |
| 2003 FY | 163.04 Million CNY | 0.0% |